Hot Investor Mandate: US-Based Fund Invests $1–3M in Seed and Series A Life Sciences, Digital Health, and Healthcare Services Companies in Women’s Health

~ Next Phase Admin ~ Leave a comment

The firm is a U.S.-based venture capital investor focused exclusively on women’s health, with investments spanning life sciences, digital health, and technology-enabled healthcare services. The firm primarily invests at the Seed and Series A stages, typically committing $1M–$3M per investment. The firm can lead or co-lead financing rounds and takes an active approach to portfolio development, often seeking board representation or observer rights. The firm primarily targets U.S.-based companies but also considers international opportunities when investment proceeds support U.S.-focused activities, including regulatory development, clinical validation, or commercialization.

The firm invests in healthcare solutions addressing conditions that exclusively or disproportionately affect women, as well as diseases where female-specific physiology creates opportunities to improve diagnosis, treatment, and clinical outcomes. The firm evaluates opportunities across therapeutics, medical devices, diagnostics, digital health, and technology-enabled healthcare delivery. Investment decisions are guided by four principal considerations: transformative innovation, access to care, affordability, and systemic improvement in healthcare delivery. The firm prioritizes technologies and business models capable of improving patient outcomes, reducing barriers to adoption, and addressing significant gaps in women’s healthcare.

From a company and management team perspective, the firm seeks differentiated healthcare solutions with strong commercial potential and a clear pathway to the U.S. market. The firm places particular emphasis on measurable patient impact, scalability, and the ability to improve healthcare accessibility and affordability. The firm takes an active role in supporting portfolio companies through strategic guidance, governance participation, business development, and commercialization planning.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: US-Based Early-Stage Life Sciences Investment Firm Backs Pre-Seed to Series A Therapeutics, MedTech, and Biotechnology Platforms

~ Next Phase Admin ~ Leave a comment

The firm is a U.S.-based life sciences venture development and investment organization focused on supporting early-stage biotechnology and medical technology companies. The firm invests from Pre-Seed through Series A and combines financial investment with laboratory infrastructure, specialized equipment, operational resources, and company-building support. The firm utilizes multiple investment structures, including direct early-stage equity investments and in-kind arrangements that provide access to laboratory facilities and other resources in exchange for equity. The firm primarily operates within major U.S. life sciences innovation ecosystems.

The firm invests exclusively in life sciences, including therapeutics, medical devices, diagnostics, biotechnology platforms, and enabling healthcare technologies. Areas of interest include drug discovery, precision medicine, oncology, cell and gene therapies, advanced diagnostics, medical technologies, and life science tools. The firm prioritizes differentiated scientific innovations with strong translational potential and meaningful clinical applications. The firm is particularly interested in very early-stage technologies emerging from academic institutions, research centers, and healthcare systems that can benefit from dedicated infrastructure and company development support.

From a company and management team perspective, the firm seeks founders and technical teams developing scientifically differentiated technologies with strong commercial potential. The firm places significant emphasis on scientific validation, technical expertise, and the ability to address substantial unmet medical needs. The firm provides hands-on support in company formation, fundraising, operational strategy, talent recruitment, and commercialization planning. The firm also facilitates access to scientific advisors, industry partners, institutional investors, and specialized research infrastructure to accelerate portfolio company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Venture Philanthropy Fund Invests $250K-2M in Early-Stage Therapeutics, Diagnostics, and Medical Technologies Addressing Neurological Conditions

~ Next Phase Admin ~ Leave a comment

The firm is a North America-based venture philanthropy investor affiliated with a private foundation dedicated to advancing research and innovation in brain tumors. The firm typically invests from Seed through Series A, with initial investments ranging from $250K–$2M and the potential for follow-on participation. The firm generally seeks to make several new investments annually and prefers to participate alongside other investors rather than lead financing rounds. The firm primarily targets companies located in the United States and Canada.

The firm focuses on technologies addressing brain tumors and related neurological conditions, including therapeutics, medical devices, diagnostics, software, and other healthcare innovations. The firm is open to a broad range of modalities and technologies, provided there is a clear or potential application in brain cancer. The firm may also consider companies initially developing technologies for other indications when the underlying approach could eventually be applied to brain tumors. For therapeutics, the firm generally prefers preclinical and early clinical-stage programs, while diagnostic technologies may be considered at later stages of clinical development.

From a company and management team perspective, the firm seeks founding teams with complementary scientific, technical, and commercial capabilities. Experience in business development, fundraising, or company building is viewed favorably but is not a strict requirement. The firm takes an active approach to supporting portfolio companies and can provide access to specialized scientific expertise, clinical research relationships, and a network of researchers and healthcare professionals.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Global Corporation Seeks Strategic Partnerships With Novel Therapeutics and Platform Technologies Across Cardiovascular, Metabolic, and Pain Indications

~ Next Phase Admin ~ Leave a comment

The firm is the U.S.-based clinical development and research organization of a diversified global pharmaceutical company. The firm is actively seeking global partnering opportunities that complement its parent company’s therapeutic pipeline and long-term research priorities. Potential partnership structures include in-licensing, co-development, co-commercialization, and other strategic collaborations. While the firm has the capacity to make direct investments, its primary focus is on strategic partnerships rather than traditional venture capital investments.

The firm focuses on novel therapeutics addressing cardiovascular disease, metabolic disorders, peripheral arterial disease, and pain management. The firm is generally stage-agnostic and is particularly interested in compounds that can be advanced through clinical proof-of-concept. Although the firm’s historical expertise centers on small molecules, the firm is expanding its interest to include antibodies, cell therapies, and other emerging therapeutic modalities. The firm also has strong interest in innovative platform technologies with potential applications across multiple therapeutic programs.

From a company and management team perspective, the firm does not impose specific requirements regarding organizational structure, management experience, or company maturity. The firm seeks differentiated therapeutic assets and technologies with strong scientific rationale, compelling development potential, and strategic alignment with its broader pharmaceutical research and development capabilities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The Problem Isn’t Access to Capital. It’s Being Investable. Why early-stage life science companies need a commercialization engine, not another introduction

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

For years, LSN ran an investment banking program for early-stage life science companies. It taught us something important: capital-raising solutions work best when a transaction is imminent. For most early-stage companies, it isn’t. Seed, Series A, and Series B companies are still working through the scientific, clinical, regulatory, commercial, and financing risks that determine whether investors will engage. They pitch technology and market potential. Investors ask what’s been proven, which risks have been retired, and what evidence is still missing. More introductions won’t close that gap. These companies need more than deal preparation. They need a commercialization process that can run for months or years.

The Commercialization Engine
LSN is building one with global partners: universities, research institutes, regional clusters, and innovation programs with technology-rich ecosystems. Our partners advance discoveries, generate evidence, and retire development risks. LSN provides assessment intelligence, investability preparation, and access to the global capital and licensing marketplace. LSN’s agentic AI engines support this process. They help evaluate companies through the eyes of investors and licensing partners, an approach already used with more than 250 clients. They also identify and rank relevant global capital and licensing targets.

Stage Commercialization Capability
Scientific assessment and de-risking Scientific and commercialization partners
Investability preparation LSN Investability Assessment, LSN Labs, de-risked decks
Partner identification LSN Matching Engine and Global Target Lists
Campaign execution BD Assist
Global partnering RESI Conference Series

Companies enter wherever their readiness puts them. Agentic AI tools are becoming widely available. LSN’s advantage is the global network, relationships, proprietary databases, and market intelligence built through years of direct work with investors, licensing partners, and companies. That depth of intelligence goes well beyond the cursory matches available from web searches.

BD Assist: Where Preparation Becomes Execution
A seasoned CEO may know a few dozen investors and can find a few hundred more. That still isn’t enough. LSN’s Matching Engine generates a Global Target List of 800–1,000 prospective capital and licensing partners. BD Assist puts that intelligence to work through sustained outreach, engagement tracking, and follow-up over the 9–18 months that early-stage campaigns can require. The CEO leads investor relationships, negotiations, and transactions. LSN manages targeting intelligence, sets up the meetings, and provides campaign support. The cost is $5,000 a month, with no success fee. LSN leverages databases that capture current and forward-looking mandates and historical VC and Pharma transactions, then integrates into all of LSN’s RESI events to add face-to-face or virtual meetings with investors and licensing partners worldwide.

Who Is the Perfect Fit for BD Assist?
The ideal client is an experienced life science CEO who knows how to raise capital and has an investable asset and a credible development plan. What they lack is the global reach and campaign infrastructure to pursue hundreds of prospective investors and licensing partners. This CEO doesn’t need someone to explain fundraising or negotiate a term sheet. They need a dedicated team to identify the right global targets, run a disciplined campaign, and keep opportunities moving while they run their company. BD Assist is not for every company that needs money. Companies still working through fundamental scientific or investability issues may first need assessment, de-risking, and preparation.

The CEO knows how to raise the money. LSN provides the global intelligence and reach, including meeting setup and campaign infrastructure, to help them find it.

To see whether BD Assist is the right fit for your company, contact the LSN team. LSN BD will provide a free investability assessment report, show you what your global target list should look like, and offer commentary on your messaging for your target audience.

Get Your LSN Labs Company Assessment Report

From BioJapan 2026 to RESI Asia 2027: Connecting Japan’s Life Science Innovation to Global Opportunities

~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Life Science Nation (LSN) was pleased to return to Yokohama for BioJapan 2026 held on October 7-9 at PACIFICO Yokohama. Known for one of Asia’s leading life sciences partnering conference hosted by the Japan Bioindustry Association (JBA), the event brought together startups, investors, pharmaceutical companies, and industry stakeholders from around the world to explore emerging innovations and opportunities for collaboration.

This year, for the first time, LSN participated in two seminars in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), focusing on helping Japanese life science startups navigate the global investment landscape. Throughout the conference, LSN emphasized the importance of investor readiness and international engagement for emerging life science companies seeking to accelerate their development and commercialization efforts.

On October 8, LSN participated in the KBIC x MEDISO Collaboration Program “Key Points for Early-Phase Global Fundraising” which brought together representative from Japan’s public and private sectors, including government delegates, venture capitalists, biotech executives, and ecosystem leaders, to discuss the challenges and opportunities associated with international fundraising for early-stage life science companies. A particularly meaningful aspect of the seminar was the opportunity to hear directly from startup CEOs who LSN has been working with on their international business development efforts. Drawing from their firsthand experiences, the discussion explored the realities of approaching global investors and navigating different investment expectations.

The following day on October 9, LSN joined KBIC for a second luncheon seminar titled “Inside Global Fundraising: LSN Framework for Startup Readiness and Global Capital Raising Success”. This session focused on broader global fundraising trends and the strategies life science startups can adopt to improve their readiness for international investment. Together, the two seminars highlighted the common message of how successful fundraising requires more than scientific excellence. It also demands a strong understanding of the perspective from global investors and the ability to build meaningful relationships across markets.

Japan’s Foundation for Global Growth within the Global Life Science Ecosystem

Japan has long been recognized as a global leader in scientific research and technological innovation. With its world-class academic institutions, established pharmaceutical industry, and growing biotechnology startups community, the country offers a strong foundation for life science innovation. The country’s scientific expertise combined with an increasingly entrepreneurial research environment, it continues to create opportunities for translating breakthrough discoveries into commercially viable solutions. Innovation hubs such as Kobe City demonstrate the importance of collaboration between academia, industry, government, and emerging companies. By fostering connections across these groups, organizations such as KBIC help strengthen the infrastructure needed to support growth of impactful life science businesses.

Japan’s strengths span multiple sectors including pharmaceutical R&D, regenerative medicine, cell and gene therapies, academic research, and the integration of healthcare with engineering and technology. However, as Japan’s biotechnology startup ecosystem continues to develop, access to international capital and strategic partnership remains an important consideration for companies seeking to expand beyond the domestic market. For early-stage companies, engaging with global investors can provide more than financial resources. International relationships can also create opportunities for clinical development, licensing, commercialization, and entry into new markets. By connecting Japan’s scientific strengths and global investment and partnering opportunities, LSN aims to help bridge the gap between promising research and international commercialization.

Continuing the Momentum to RESI Asia 2027 in Tokyo

Building on the discussions and relationships established at BioJapan, LSN is excited to continue supporting the Japanese life science ecosystem through RESI Asia 2027, taking place on April 13, 2027 at the ANA InterContinental Tokyo Hotel, with KBIC as our co-developer. As part of LSN’s globally recognized RESI Conference Series, RESI Asia is designed to connect early-stage life science and healthcare startups with investors, pharmaceutical companies, and strategic partners seeking innovative technologies and new business development opportunities. The conference will also offer virtual partnering on April 15-16 and 19-20, extending the opportunity for international engagement beyond the in-person event.

The conference will bring together not just participants from Japan and across Asia, but also around the world, creating a dedicated platform for cross-border investment and strategic collaboration. The conference will feature startups in Pre-Seed through Series B stages across therapeutics, medical devices, diagnostics, and digital health, offering international investors and pharmaceutical companies direct access to promising companies from Japan, the broader Asian life science ecosystem, and around the world.

From BioJapan 2026 to RESI Asia 2027, LSN remains committed to supporting Japan’s life science innovators as they connect with the global investment community. We look forward to continuing our collaborations with KBIC and the broader Japanese life science ecosystem and welcoming startups, investors, and strategic partners to Tokyo next April!

RESI Asia Japan Registration:

Japan-base Registration (JPY)
Non-Japan-base Registration (USD)

The JPM Reality Check: Why Early-Stage Life Science Companies Struggle in San Francisco, and Why RESI Is the Best Fit for You

~ Next Phase Admin ~ Leave a comment

By Caitlin Dolegowski, Program Director, LSN

Every January, tens of thousands of healthcare executives head to San Francisco for J.P. Morgan Healthcare Week. The conventional advice given to founders is simple: “You have to be there.”

So founders book non-refundable flights, secure hotel rooms topping $1,000 a night, and arrive with high hopes. Within 48 hours, reality sets in:

  • The Calendar Lockout: Institutional venture capital funds and big pharma search and evaluation teams do not leave schedules open for casual run-ins. Their diaries are locked down weeks before the conference begins.
  • The “Lobby Chasing” Trap: Founders end up pitching sensitive science in crowded hotel lobbies, shouting over espresso machines and cold-messaging investors on LinkedIn with little to no response.
  • The Stage Mismatch: The official, invitation-only JPM conference is built primarily for public companies, late-stage clinical assets, and large institutional asset allocators. If you are raising Seed, Series A, or Series B, the main conference is not built for your deal size.

The hard part of early-stage fundraising during JPM Week is not the pitch. It is qualified access.

To turn JPM Week into a strategic milestone rather than an expensive distraction, early-stage innovators need a dedicated, mandate-driven partnering ecosystem.

Why RESI JPM Is the Premier Partnering Anchor for Emerging Life Science

Held in person on January 11 and 12 at the San Francisco Marriott Marquis, followed by three virtual partnering days on January 13, 18, and 19, RESI JPM (Redefining Early Stage Investments) was engineered specifically to solve the structural challenges early-stage companies face.

  1. Buy-Side Density Over Vanity Numbers

Unlike conventions that inflate attendance with service vendors and non-investors, RESI focuses on buy-side capital. The conference convenes over 850 active capital allocators—including venture funds, corporate venture capital (CVC) arms, family offices, and pharma business development scouts actively seeking Seed to Series B assets across therapeutics, medical devices, diagnostics, and digital health.

  1. Mandate-Specific 1-on-1 Partnering

RESI’s proprietary partnering system eliminates guesswork. Founders can filter the entire investor directory by therapeutic indication, modality, development stage, and check size before arriving in San Francisco. Meetings are confirmed in advance and held at reserved, numbered tables inside the Yerba Buena Ballroom, saving hours of transit.

  1. The 5-Day Hybrid Advantage

JPM moves at breakneck speed. By combining two intensive in-person days (Jan 11–12) with three dedicated virtual partnering days (Jan 13, 18, and 19), founders can conduct immediate follow-ups with local investors and access a massive cohort of international and cross-border funds participating remotely.

  1. The Innovator’s Pitch Challenge (IPC)

Startups seeking elevated visibility can apply to pitch live in front of active investor panels. Finalists receive dedicated exhibition poster space on the main floor and direct, scored evaluation feedback sheets from judges following the session.

Three Rules to Make Your JPM Week Count

  1. Stop Relying on Serendipity: Hoping to meet the right investor in a hotel lobby is not a fundraising strategy. High-yield JPM deals are born from targeted meetings booked in advance through formal partnering platforms.
  1. Anchor Your Geography: Crossing San Francisco between Union Square and Mission Bay can eat up an hour. Establish your base camp at an established hub like RESI inside the Marriott Marquis to eliminate transit friction.
  1. Diversify Your Capital Sources: Look beyond traditional venture funds. Tap into family offices, foundation endowments, and strategic corporate partners who are actively seeking early-stage co-investments.

Explore the RESI JPM 2027 partnering platform, review confirmed investors, and register today at RESIConference.com or contact resi@lifesciencenation.com.

Register for RESI JPM 2027